ProQR Therapeutics N.V. (PRQR)

2.29 -1.29% (-0.03)

Over 1M: +33.1%

2026-08-28
1.75 2 2.25
31 Jul 5 Aug 10 Aug 13 Aug 18 Aug 21 Aug 26 Aug

Financials Quarterly

Q1 '21 — Operating Cash Flow: -11.8M Q1 '21 — Free Cash Flow: -11.8M Q1 '21 — Net Income: -12.6M Q2 '21 — Revenue: 243K Q2 '21 — Operating Cash Flow: -10M Q2 '21 — Free Cash Flow: -10M Q2 '21 — Net Income: -15.8M Q3 '21 — Revenue: 872K Q3 '21 — Operating Cash Flow: -8.1M Q3 '21 — Free Cash Flow: -8.2M Q3 '21 — Net Income: -15.1M Q4 '21 — Revenue: 239K Q4 '21 — Operating Cash Flow: 3.8M Q4 '21 — Free Cash Flow: 3.6M Q4 '21 — Net Income: -18.2M Q1 '22 — Revenue: 1.1M Q1 '22 — Operating Cash Flow: -20.5M Q1 '22 — Free Cash Flow: -20.7M Q1 '22 — Net Income: -14.1M Q2 '22 — Revenue: 930K Q2 '22 — Operating Cash Flow: -14.8M Q2 '22 — Free Cash Flow: -15.1M Q2 '22 — Net Income: -13.5M Q3 '22 — Revenue: 814K Q3 '22 — Operating Cash Flow: -15.4M Q3 '22 — Free Cash Flow: -15.6M Q3 '22 — Net Income: -23.3M Q4 '22 — Revenue: 720K Q4 '22 — Operating Cash Flow: -17.8M Q4 '22 — Free Cash Flow: -17.8M Q4 '22 — Net Income: -13.3M Q1 '23 — Revenue: 655K Q1 '23 — Operating Cash Flow: 44.7M Q1 '23 — Free Cash Flow: 44.6M Q1 '23 — Net Income: -8.9M Q2 '23 — Revenue: 1.2M Q2 '23 — Operating Cash Flow: -10.3M Q2 '23 — Free Cash Flow: -10.6M Q2 '23 — Net Income: -8M Q3 '23 — Revenue: 1.4M Q3 '23 — Operating Cash Flow: -7.5M Q3 '23 — Free Cash Flow: -7.8M Q3 '23 — Net Income: -5.4M Q4 '23 — Revenue: 3.3M Q4 '23 — Operating Cash Flow: -5.3M Q4 '23 — Free Cash Flow: -5.9M Q4 '23 — Net Income: -5.5M Q1 '24 — Revenue: 4.5M Q1 '24 — Operating Cash Flow: -15.1M Q1 '24 — Free Cash Flow: -15.9M Q1 '24 — Net Income: -7.7M Q2 '24 — Revenue: 6.3M Q2 '24 — Operating Cash Flow: -6.3M Q2 '24 — Free Cash Flow: -6.5M Q2 '24 — Net Income: -2.7M Q3 '24 — Revenue: 3.8M Q3 '24 — Operating Cash Flow: -5.7M Q3 '24 — Free Cash Flow: -5.9M Q3 '24 — Net Income: -8.1M Q4 '24 — Revenue: 4.3M Q4 '24 — Operating Cash Flow: -9.3M Q4 '24 — Free Cash Flow: -9.5M Q4 '24 — Net Income: -9.3M Q1 '25 — Revenue: 4.5M Q1 '25 — Operating Cash Flow: -15.8M Q1 '25 — Free Cash Flow: -16M Q1 '25 — Net Income: -10.1M Q2 '25 — Revenue: 3.8M Q2 '25 — Operating Cash Flow: -11.4M Q2 '25 — Free Cash Flow: -11.5M Q2 '25 — Net Income: -12.2M Q3 '25 — Revenue: 2.9M Q3 '25 — Operating Cash Flow: -12.2M Q3 '25 — Free Cash Flow: -12.4M Q3 '25 — Net Income: -11M Q4 '25 — Revenue: 4.7M Q4 '25 — Operating Cash Flow: -13.4M Q4 '25 — Free Cash Flow: -13.9M Q4 '25 — Net Income: -8.9M -15M 0 15M 30M 45M
Q2 '21 Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25
Revenue Operating Cash Flow Free Cash Flow Net Income

Figures as at 2025-12-31, reported in EUR. The newest fact in the filings is dated 2025-12-31, 242 days ago. Nothing on this page is advice.

How it scores

Five questions, each answered by the measures under it. Every figure is the company's own; the bar beside it is where that figure sits among the companies read here — the top fifth, the bottom fifth, or somewhere between. Not among all listed companies, and for a valuation multiple the low end is the good end.

Quality

How much of the revenue is really kept — and what did it take to earn it?

0.6
SBC / sales 25.2%
OE margin -363.5%
Oper. margin -273.1%
Accruals 9.4%
EBITDA margin -256.1%
FCF margin -338.3%
OCF margin -331.9%
Profit margin -265.2%
ROA -37.4%
ROCE -54.1%
ROE -85.4%
Gross margin —
OCF / EBIT —
ROIC —

4 of 17 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Valuation

What does the price ask for what the company earns, owns and pays out?

0.5
Div. yield —
EV/EBIT —
EV/GP —
EV/OE —
EV/Sales —
FCF yield —
Fwd P/E —
P/B —
P/C —
P/E —
PEG —

0 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Durability

How predictable is the revenue, and how much of it is already committed?

0.5
RPO / sales —
RPO growth —
Segment HHI —

0 of 7 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Resilience

Can the balance sheet absorb a bad year?

6.5
ND/EBITDA —
Interest cover -83.7×
Cash / Debt 19.0×
Debt / Eq 0.099×
Debt payback 0.0 yr
Quick ratio 3.1×
Cash runway 1.6 yr
F-score —
Payout —

3 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Growth

Is the business getting bigger, and is it getting more profitable?

1.0
Sales/sh Y/Y -31.2%
Sales Q/Q +8.8%
Shares change +22.4%
Div. growth —
EBIT CAGR —
EBIT Y/Y —
EPS CAGR 4Y —
EPS Y/Y —
EPS next Y —
Sales CAGR 4Y —

1 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

A measure absent from a block could not be computed from this company's filings. It is left out rather than scored as though it were bad, and the dimension is averaged over what remains. A score is measured against a fixed scale this model states; the bar is measured against the other companies, so the two can disagree — and where they do, that disagreement is the more interesting figure.